How Should We Deal with Missing Data in Clinical Trials Involving Alzheimer's Disease Patients?

E-ISSN： 1875-5828|8|4|421-433

ISSN： 1567-2050

Source： Current Alzheimer Research, Vol.8, Iss.4, 2011-06, pp. : 421-433

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Should a diagnosis of Alzheimer's disease be disclosed?

By Sullivan K. O'Conor F.

Aging and Mental Health, Vol. 5, Iss. 4, 2001-11 ,pp. : 340-348

Routledge Ltd

Access to resources Recommend Favorite

Should combined pharmaco- and psychotherapy be offered to depressed patients?: A qualitative review of randomized clinical trials from the 1990s

By Hegerl Ulrich Plattner Anita Möller Hans-Jürgen

European Archives of Psychiatry and Clinical Neuroscience, Vol. 254, Iss. 2, 2004-04 ,pp. : 99-107

Springer Publishing Company

Access to resources Recommend Favorite

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): Baseline Characteristics

Current Alzheimer Research, Vol. 4, Iss. 3, 2007-07 ,pp. : 325-335

Bentham Science Publishers

Access to resources Recommend Favorite

A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials

Current Alzheimer Research, Vol. 15, Iss. 5, 2018-03 ,pp. : 429-442

Bentham Science Publishers

Access to resources Recommend Favorite

How should we inform patients about antidepressants? A study comparing verbal and written information

By Gundogar Duru Demirci Serpil Uluhan Filiz

International Journal of Psychiatry in Clinical Practice, Vol. 11, Iss. 3, 2007-01 ,pp. : 212-217

Ashgate Publishing Ltd

Access to resources Recommend Favorite